News and outlook
- Advanced BioDesign continues to recruit patients for its first-in-man clinical trial “ODYSSEY” of its drug candidate ABD-3001 targeting acute myeloid leukemia (AML) – (EudraCT N°: 2021-003159-4). The first 3 doses were well tolerated by patients (with no dose-limiting toxicity or DLT, and no serious adverse events or SAE). A phase II trial in Europe is planned in AML from the end of 2025. In parallel, ABD is accelerating the preclinical development of a second-generation ALDH inhibitor (ALDHi), ABD-0171. This second lead is currently under development (pharmaceutical scale-up, formulation, clinical proof-of-concept, combination studies, etc). ABD-0171 could be evaluated in a clinical trial in solid tumors from 2026.
- Advanced BioDesign is continuing R&D to consolidate proof-of-concept in cancer indications where medical needs are high, and in particular in solid tumor indications. Investigations are underway in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), in addition to AML.
- Advanced BioDesign is the winner of the “i-Demo” call for projects launched by BPI as part of “France 2030 plan”: the “ODYSSEY” clinical study will be funded with a €3.2 million grant over 3 years. Today, 30% of its research budget is funded by non-dilutive public aid.
ADVANCED BIODESIGN, WINNER OF THE FRANCE 2030 PLAN’S CALL FOR “i-DEMO” PROJECTS TO FINANCE ITS “ODYSSEY” CLINICAL TRIAL WITH UP TO €3M
Advanced BioDesign's winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia ...
ADVANCED BIODESIGN ANNOUNCES THE START OF THE FIRST-IN-HUMAN CLINICAL TRIAL “ODYSSEY” TARGETING ACUTE MYELOID LEUKAEMIA
After receiving an approval from the National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announces today the ...
ADVANCED BIODESIGN ANNOUNCES THAT IT HAS OBTAINED FUNDING FOR ITS CRISPALDHin PROJECT AS PART OF THE RELAUNCH FRANCE PLAN
Advanced BioDesign and the Inserm TAGC laboratory will receive a total of €208,000 to support the development of their CRISPALDHin ...